Cargando…

In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum

BACKGROUND: There is an urgent need for the discovery of new anti-malarial drugs and combination therapy. A combinatorial approach protects each drug from the development of resistance and reduces generally the overall transmission rate of malaria. Statins, the inhibitors of 3-hydroxy-3-methylglutar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dormoi, Jérome, Savini, Hélène, Amalvict, Rémy, Baret, Eric, Pradines, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045961/ https://www.ncbi.nlm.nih.gov/pubmed/24886347 http://dx.doi.org/10.1186/1475-2875-13-189

Ejemplares similares

Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum
por: Parquet, Véronique, et al.
Publicado: (2010)

Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine
por: Pascual, Aurélie, et al.
Publicado: (2015)

Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model
por: Souraud, Jean-Baptiste, et al.
Publicado: (2012)

In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene
por: Pascual, Aurélie, et al.
Publicado: (2013)

Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum
por: Pradines, Bruno, et al.
Publicado: (2010)

Use of the atmospheric generators for capnophilic bacteria Genbag-CO2 for the evaluation of in vitro Plasmodium falciparum susceptibility to standard anti-malarial drugs
por: Pascual, Aurélie, et al.
Publicado: (2011)

Methylene Blue-Based Combination Therapy with Amodiaquine Prevents Severe Malaria in an Experimental Rodent Model
por: Dormoi, Jérôme, et al.
Publicado: (2022)

In vitro susceptibility to quinine and microsatellite variations of the Plasmodium falciparum Na(+)/H(+ )exchanger (Pfnhe-1) gene: the absence of association in clinical isolates from the Republic of Congo
por: Briolant, Sébastien, et al.
Publicado: (2011)

Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
por: Assefa, Ashenafi, et al.
Publicado: (2022)

In vitro susceptibility to pyrimethamine of DHFR I164L single mutant Plasmodium falciparum
por: Andriantsoanirina, Valérie, et al.
Publicado: (2011)

Correction: Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
por: Assefa, Ashenaf, et al.
Publicado: (2023)

Plasmodium falciparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014
por: Fall, Bécaye, et al.
Publicado: (2016)

Electrocardiographic effect of artemisinin-piperaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine treatment in falciparum malaria patients
por: Wu, Wanting, et al.
Publicado: (2021)

Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015
por: Plucinski, Mateusz M., et al.
Publicado: (2017)

The Plasmodium falciparum chloroquine resistance transporter is associated with the ex vivo P. falciparum African parasite response to pyronaridine
por: Madamet, Marylin, et al.
Publicado: (2016)

Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model
por: Dormoi, Jérome, et al.
Publicado: (2013)

Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children
por: Nambozi, Michael, et al.
Publicado: (2011)

Efficacy of artesunate–amodiaquine, dihydroartemisinin–piperaquine and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger
por: Grandesso, Francesco, et al.
Publicado: (2018)

A randomized trial of dihydroartemisinin–piperaquine versus artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali
por: Dama, Souleymane, et al.
Publicado: (2018)

Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates
por: Foguim, Francis Tsombeng, et al.
Publicado: (2020)

Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on Plasmodium Falciparum Drug Sensitivity-Associated Haplotypes in Uganda
por: Taylor, Aimee R., et al.
Publicado: (2016)

Recurrence of Plasmodium malariae and P. falciparum Following Treatment of Uncomplicated Malaria in North Sumatera With Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine
por: Lubis, Inke Nadia D, et al.
Publicado: (2020)

Artemether–lumefantrine and dihydroartemisinin–piperaquine treatment outcomes among children infected with uncomplicated Plasmodium falciparum malaria in Mwanza, Tanzania
por: Marwa, Karol J., et al.
Publicado: (2021)

Prevalence of Mutations in the pfcoronin Gene and Association with Ex Vivo Susceptibility to Common Quinoline Drugs against Plasmodium falciparum
por: Delandre, Océane, et al.
Publicado: (2021)

Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model
por: Dormoi, Jérôme, et al.
Publicado: (2013)

Plasmodium berghei ANKA: Selection of resistance to piperaquine and lumefantrine in a mouse model
por: Kiboi, D.M., et al.
Publicado: (2009)

The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum
por: Chotivanich, Kesinee, et al.
Publicado: (2012)

Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015
por: Diawara, Silman, et al.
Publicado: (2017)

Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment
por: Omondi, Protus, et al.
Publicado: (2019)

Efficacy and safety of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017
por: Davlantes, Elizabeth, et al.
Publicado: (2018)

Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model
por: Gimode, Winnie R, et al.
Publicado: (2015)

Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa
por: Yavo, William, et al.
Publicado: (2011)

Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
por: Pascual, Aurélie, et al.
Publicado: (2012)

High therapeutic efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Somalia
por: Warsame, Marian, et al.
Publicado: (2019)

Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial
por: Hamaluba, Mainga, et al.
Publicado: (2021)

Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children
por: Nji, Akindeh M, et al.
Publicado: (2015)

Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria
por: Zani, Babalwa, et al.
Publicado: (2014)

Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area
por: Song , Jianping, et al.
Publicado: (2011)

Treatment of Asymptomatic Carriers of Plasmodium falciparum with Artemether–Lumefantrine: Impact on the Prevalence of Anemia
por: Tiono, Alfred B., et al.
Publicado: (2013)

Comparative study of the efficacy and tolerability of dihydroartemisinin - piperaquine - trimethoprim versus artemether - lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal
por: Menan, Hervé, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hiu36esn82sa4klbkdaq8hito4